Here is an article detailing the appointment of Professor Iris Loew-Friedrich, MD, as a Clinical and R&D Advisor for iQure Pharma:
iQure Pharma Strengthens Clinical and R&D Leadership with Appointment of Professor Iris Loew-Friedrich, MD
[City, State] – July 2, 2025 – iQure Pharma, a forward-thinking biopharmaceutical company dedicated to developing innovative therapies, is pleased to announce the appointment of Professor Iris Loew-Friedrich, MD, as a Clinical and R&D Advisor. This strategic appointment brings a wealth of experience and renowned expertise from the global pharmaceutical landscape to iQure Pharma, further bolstering its commitment to scientific excellence and clinical advancement.
Professor Loew-Friedrich joins iQure Pharma with an exceptional track record in the biopharmaceutical industry, most notably her distinguished tenure as Chief Medical Officer and Head of Development at UCB, a leading global biopharmaceutical company. During her impactful leadership at UCB, she was instrumental in driving the development and approval of numerous significant therapies across various therapeutic areas, demonstrating a profound understanding of drug development from early-stage research through to successful market launch.
In her new role as Clinical and R&D Advisor at iQure Pharma, Professor Loew-Friedrich will provide invaluable strategic guidance and expert counsel on the company’s clinical development programs and research initiatives. Her deep insights into regulatory pathways, clinical trial design, and the strategic landscape of biopharmaceutical innovation are expected to be instrumental in accelerating iQure Pharma’s pipeline and achieving key developmental milestones.
“We are incredibly honored and excited to welcome Professor Iris Loew-Friedrich to iQure Pharma,” said [Name and Title of iQure Pharma CEO or relevant executive, if available in the source, otherwise omit or use a generic title like “a spokesperson for iQure Pharma”]. “Her unparalleled experience in leading global R&D and clinical operations at a major pharmaceutical company is a tremendous asset. Professor Loew-Friedrich’s strategic vision and proven ability to navigate the complexities of drug development will undoubtedly play a pivotal role in shaping our scientific direction and advancing our mission to bring life-changing medicines to patients.”
Professor Loew-Friedrich’s appointment underscores iQure Pharma’s dedication to attracting top-tier talent and leveraging world-class expertise to foster innovation and drive success in the competitive biopharmaceutical sector. Her advisory role will be crucial in guiding the company’s scientific strategy, ensuring rigorous clinical execution, and maximizing the potential of its promising therapeutic candidates.
The addition of Professor Loew-Friedrich to iQure Pharma’s advisory board signifies a significant step forward in the company’s growth and development. iQure Pharma remains committed to its patient-centric approach and looks forward to the valuable contributions Professor Loew-Friedrich will make in advancing its pipeline and ultimately improving patient outcomes.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor’ at 2025-07-02 14:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.